Clinical Trials Logo
  1. Home
  2. Myeloid Malignancies
  3. NCT05807659

Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies

Myeloid Malignancies Clinical Trial

Official title:
Fractionated Busulfan Combined With Chidamide/Fludarabine/Cytarabine (ChiFAB) With Allogeneic Hematopoietic Stem-Cell Transplantation in Non-remission Myeloid Malignancies: a Phase II Study

Clinical Trial Summary

The goal of this single-arm phase II study is to test in patients with non-remission myeloid malignancies undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer are: - The safety and efficacy of fractionated busulfan Combined With Chidamide/Fludarabine/Cytarabine(ChiFAB) conditioning regimen in increasing the overall survival rate in patients with non-remission myeloid malignancies after allo-HSCT. - The efficacy of fractionated busulfan conditioning regimen in reducing the recurrence rate in patients with non-remission myeloid malignancies after allo-HSCT. Participants will receive fractionated busulfan-based ChiFAB conditioning regimen (busulfan 3.2mg/kg d-13, -12, 1.6mg/kg d-6~-3, fludarabine 35mg/m2 d-6~-2, cytarabine 1g/m2,d-6~-2, chidamide 30mg d-13,-10,-6,-3) before allo-HSCT.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05807659
Study type Interventional
Source Sichuan University
Contact
Status Recruiting
Phase Phase 2
Start date March 16, 2023
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06383572 - Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies Phase 1/Phase 2
Completed NCT01731951 - Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis Phase 2
Recruiting NCT02958397 - A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies Phase 1/Phase 2
Recruiting NCT02958384 - A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies Phase 1/Phase 2
Recruiting NCT05775406 - Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Phase 1
Active, not recruiting NCT02452697 - Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT Phase 2
Completed NCT04778410 - Study of Magrolimab Combinations in Participants With Myeloid Malignancies Phase 2
Terminated NCT01366612 - PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Phase 3
Completed NCT03270748 - Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies Phase 2
Recruiting NCT05115630 - Off-the-shelf NK Cells + SCT for Myeloid Malignancies Phase 1/Phase 2
Recruiting NCT05796570 - A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies Phase 2